BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8365641)

  • 1. Effect of ebrotidine on the synthesis and secretion of gastric sulfomucin.
    Slomiany BL; Lopez RA; Liau YH; Slomiany A
    Gen Pharmacol; 1993 May; 24(3):611-7. PubMed ID: 8365641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and secretion of gastric sulfomucin in the presence of ebrotidine, a new antiulcer agent.
    Slomiany BL; Lopez RA; Slomiany A
    Biochem Int; 1992 Dec; 28(4):665-74. PubMed ID: 1482403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitecapone effect on the synthesis and secretion of gastric sulfomucin.
    Slomiany BL; Liau YH; Lopez RA; Slomiany A
    Gen Pharmacol; 1993 Jan; 24(1):69-73. PubMed ID: 8387047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Helicobacter pylori lipopolysaccharide effect on the synthesis and secretion of gastric sulfomucin.
    Liau YH; Lopez RA; Slomiany A; Slomiany BL
    Biochem Biophys Res Commun; 1992 May; 184(3):1411-7. PubMed ID: 1590801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of gastric mucus phospholipid secretion by an antiulcer agent, ebrotidine.
    Slomiany BL; Piotrowski E; Piotrowski J; Zirvi KA; Liau YH; Murty VL; Slomiany A
    Gen Pharmacol; 1994 Sep; 25(5):1033-7. PubMed ID: 7835621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helicobacter pylori aggregating activity of gastric mucin with ulcer healing by ebrotidine.
    Piotrowski J; Majka J; Piotrowski E; Murty VL; Gabryelewicz A; Slomiany A; Slomiany BL
    Biochem Mol Biol Int; 1994 Nov; 34(5):875-81. PubMed ID: 7535617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastroprotective properties of ebrotidine. A review.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of sulfation in the processing of gastric mucins.
    Liau YH; Murty VL; Slomiany A; Bielanski W; Slomiany BL
    J Physiol Pharmacol; 1991 Dec; 42(4):357-66. PubMed ID: 1726711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine.
    Slomiany BL; Liu J; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
    J Physiol Pharmacol; 1994 Mar; 45(1):121-31. PubMed ID: 7519082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement in the protective qualities of gastric mucus by ebrotidine during duodenal ulcer healing.
    Slomiany BL; Piotrowski J; Majka J; Czajkowski A; Slomiany A; Gabryelewicz A
    Gen Pharmacol; 1995 Sep; 26(5):1039-44. PubMed ID: 7557247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastric mucosal EGF and PDGF receptor expression with ulcer healing by ebrotidine.
    Slomiany BL; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
    Am J Gastroenterol; 1994 Jun; 89(6):894-7. PubMed ID: 8198101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ebrotidine effect on the proteolytic and lipolytic activities of Helicobacter pylori.
    Slomiany BL; Piotrowski J; Mojtahed H; Slomiany A
    Gen Pharmacol; 1992 Mar; 23(2):203-6. PubMed ID: 1639232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of gastric mucosal mucin receptor by H. pylori lipopolysaccharide: effect of ebrotidine.
    Slomiany BL; Piotrowski J; Murty VL; Slomiany A
    Gen Pharmacol; 1995 Nov; 26(7):1553-8. PubMed ID: 8690245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of tumor necrosis factor-alpha and apoptosis in gastric mucosal injury by indomethacin: effect of omeprazole and ebrotidine.
    Slomiany BL; Piotrowski J; Slomiany A
    Scand J Gastroenterol; 1997 Jul; 32(7):638-42. PubMed ID: 9246701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of ebrotidine protection against gastric mucosal injury induced by ethanol.
    Slomiany BL; Piotrowski J; Murty VL; Slomiany A
    Gen Pharmacol; 1992 Jul; 23(4):719-27. PubMed ID: 1356875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of sulfation in post-translational processing of gastric mucins.
    Liau YH; Slomiany A; Slomiany BL
    Int J Biochem; 1992 Jul; 24(7):1023-8. PubMed ID: 1383042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ebrotidine on gastric mucosal calcium channel activity.
    Slomiany BL; Liu J; Kawai T; Czajkowski A; Slomiany A
    Am J Gastroenterol; 1993 Jun; 88(6):881-6. PubMed ID: 8099251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of gastric somatostatin receptor inhibition by Helicobacter pylori lipopolysaccharide with ebrotidine and sulglycotide.
    Piotrowski J; Skrodzka D; Slomiany A; Slomiany BL
    Gen Pharmacol; 1997 May; 28(5):705-8. PubMed ID: 9184806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
    Piotrowski J; Yamaki K; Morita M; Slomiany A; Slomiany BL
    Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.